View in EDS

Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma.

Saved in:
Bibliographic Details
Title: Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma.
Authors: Yu K; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tidwell RS; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bathala TK; Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sheth RA; Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Karki M; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas., Chen J; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas., Qian J; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas., Duan F; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas., Perelli L; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Soeung M; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Rao P; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Siefker-Radtke AO; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Daw NC; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ingram DR; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Shamsutdinova D; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wani KM; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wang WL; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lazar AJ; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zhao Z; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Prabhakaran S; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bota-Rabassedas N; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Futreal A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yang L; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences (GSBS), Houston, Texas., Lin C; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences (GSBS), Houston, Texas., Genovese G; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas., Gao J; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wang L; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences (GSBS), Houston, Texas.; The James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Institute for Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tannir NM; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Msaouel P; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences (GSBS), Houston, Texas.
Corporate Authors: Rare Tumor Initiative Team, Patient Mosaic Team
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2026 May 15; Vol. 32 (10), pp. 1946-1961.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42007903
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Yu+K%22">Yu K</searchLink>; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Tidwell+RS%22">Tidwell RS</searchLink>; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Bathala+TK%22">Bathala TK</searchLink>; Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Sheth+RA%22">Sheth RA</searchLink>; Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Karki+M%22">Karki M</searchLink>; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Chen+J%22">Chen J</searchLink>; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Qian+J%22">Qian J</searchLink>; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Duan+F%22">Duan F</searchLink>; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Perelli+L%22">Perelli L</searchLink>; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Soeung+M%22">Soeung M</searchLink>; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Rao+P%22">Rao P</searchLink>; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Siefker-Radtke+AO%22">Siefker-Radtke AO</searchLink>; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Daw+NC%22">Daw NC</searchLink>; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Ingram+DR%22">Ingram DR</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Shamsutdinova+D%22">Shamsutdinova D</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Wani+KM%22">Wani KM</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Wang+WL%22">Wang WL</searchLink>; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Lazar+AJ%22">Lazar AJ</searchLink>; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Zhao+Z%22">Zhao Z</searchLink>; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Prabhakaran+S%22">Prabhakaran S</searchLink>; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Bota-Rabassedas+N%22">Bota-Rabassedas N</searchLink>; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Futreal+A%22">Futreal A</searchLink>; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Yang+L%22">Yang L</searchLink>; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences (GSBS), Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Lin+C%22">Lin C</searchLink>; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences (GSBS), Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Genovese+G%22">Genovese G</searchLink>; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Gao+J%22">Gao J</searchLink>; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Wang+L%22">Wang L</searchLink>; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences (GSBS), Houston, Texas.; The James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Institute for Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Tannir+NM%22">Tannir NM</searchLink>; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Msaouel+P%22">Msaouel P</searchLink>; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences (GSBS), Houston, Texas.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22Rare+Tumor+Initiative+Team%22">Rare Tumor Initiative Team</searchLink><br /><searchLink fieldCode="CA" term="%22Patient+Mosaic+Team%22">Patient Mosaic Team</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502500%22">Clinical cancer research : an official journal of the American Association for Cancer Research</searchLink> [Clin Cancer Res] 2026 May 15; Vol. 32 (10), pp. 1946-1961.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502500 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1557-3265 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210780432%22">10780432 </searchLink><i>NLM ISO Abbreviation: </i>Clin Cancer Res <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42007903
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1078-0432.CCR-25-4518
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1946
    Titles:
      – TitleFull: Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Yu K
      – PersonEntity:
          Name:
            NameFull: Tidwell RS
      – PersonEntity:
          Name:
            NameFull: Bathala TK
      – PersonEntity:
          Name:
            NameFull: Sheth RA
      – PersonEntity:
          Name:
            NameFull: Karki M
      – PersonEntity:
          Name:
            NameFull: Chen J
      – PersonEntity:
          Name:
            NameFull: Qian J
      – PersonEntity:
          Name:
            NameFull: Duan F
      – PersonEntity:
          Name:
            NameFull: Perelli L
      – PersonEntity:
          Name:
            NameFull: Soeung M
      – PersonEntity:
          Name:
            NameFull: Rao P
      – PersonEntity:
          Name:
            NameFull: Siefker-Radtke AO
      – PersonEntity:
          Name:
            NameFull: Daw NC
      – PersonEntity:
          Name:
            NameFull: Ingram DR
      – PersonEntity:
          Name:
            NameFull: Shamsutdinova D
      – PersonEntity:
          Name:
            NameFull: Wani KM
      – PersonEntity:
          Name:
            NameFull: Wang WL
      – PersonEntity:
          Name:
            NameFull: Lazar AJ
      – PersonEntity:
          Name:
            NameFull: Zhao Z
      – PersonEntity:
          Name:
            NameFull: Prabhakaran S
      – PersonEntity:
          Name:
            NameFull: Bota-Rabassedas N
      – PersonEntity:
          Name:
            NameFull: Futreal A
      – PersonEntity:
          Name:
            NameFull: Yang L
      – PersonEntity:
          Name:
            NameFull: Lin C
      – PersonEntity:
          Name:
            NameFull: Genovese G
      – PersonEntity:
          Name:
            NameFull: Gao J
      – PersonEntity:
          Name:
            NameFull: Wang L
      – PersonEntity:
          Name:
            NameFull: Tannir NM
      – PersonEntity:
          Name:
            NameFull: Msaouel P
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 05
              Text: 2026 May 15
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1557-3265
          Numbering:
            – Type: volume
              Value: 32
            – Type: issue
              Value: 10
          Titles:
            – TitleFull: Clinical cancer research : an official journal of the American Association for Cancer Research
              Type: main
ResultId 1